This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Glenmark looks to face US DOJ's antitrust claims over drugs separate from Teva

( July 23, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Glenmark has asked a US judge to sever antitrust claims filed against it by the Department of Justice over the drug pravastatin from claims against Teva Pharmaceuticals. “Counts Two and Three do not mention Glenmark or pravastatin and instead allege distinct conspiracies involving several other companies and nine different specified medications. Counts Two and Three likewise allege different means and methods and overt acts occurring at different times. The only connection between the three counts is the alleged involvement of Teva Pharmaceuticals USA. That is not enough to join these unrelated counts in a single trial,” it said.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections